undamentalytics Newsletter
Sign in

Roivant Sciences Ltd. cash flow statement

In fiscal 2026, Roivant Sciences Ltd.'s operations generated −$750m of cash; it spent $8.2m on capital projects, leaving free cash flow of −$759m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash from operations−552−678−843−765−839−750−816
Depreciation and amortisation—619221433
Stock-based pay85565218200289346347
Capital spending617131585
Free cash flow−558−695−856−767−844−759−821
Free cash flow after stock pay−643−1,260−1,074−966−1,133−1,105−1,168
Share buybacks——001,293——
Shares issued—031220000—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EVAX vs ROIVADAG vs ROIVROIV vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Roivant Sciences Ltd.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Roivant Sciences Ltd.